Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06318169 is registered in ClinicalTrials.gov with 89bio, Inc. as lead sponsor.

NCT NCT06318169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06318169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Lead sponsor
89bio, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 13, 2024
Completion date
February 28, 2029
Enrollment
1,350 (estimated)
Sites
370

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease (mash) / nonalcoholic steatohepatitis (nash) with fibrosis